Temple University Field of Pharmacogenetics Questions

QUESTION 1 

Create your initial post on the DQ 4 Discussion Board in response to the following questions: 

Consider the cost/benefit analysis of genetic tests of important pharmacogenetic variants prior to placing a patient on a new medication. Those placed in charge of patient treatment as clinicians (who are primarily tasked with patient health) or as health care system administrators (who are tasked with keeping the system financially solvent) often have competing mandates. How would you try to craft a general policy for pharmacogenetic testing?

Return to the board and read over the posts of your fellow classmates. Choose at least one classmate and create a post responding to his/her initial post on the Discussion Board.

2.QUESTION 2 

Create your initial post in response to the following:

Provide a link to a news piece related to drug approval.

Return to the board and read over the posts of your fellow classmates. Choose at least one classmate and create a post responding to his/her initial post on the Discussion Board.

3.QUESTION 

Create your initial post in response to the following:

Provide one reason why it is important to run clinical studies globally.

response post question 1 pharmacology

I would make a policy that genetic testing would only be done in subjects that had underlying conditions that would affect the metabolism of the drug or for high risk medication. In addition patients that have not been able to receive diagnosis for illness (inconclusive testing for titers or metabolites) should undergo genetic testing to determine suitability for medications for their treatment of symptoms. This will reduce the cost, while also allowing for patient safety when required. This doesn’t necessarily stop conditions like Steven Johnson syndrome from occurring, but can help reduce it. Another factor with creating policy for genetic testing should be patient history, as that can give insight to allergies and certain medical events that would prevent a patient from taking a medication that may aggravate their condition or health.

give response post for this buddy

question 2 response post

My mom has multiple sclerosis, and is doing quite well with her current medication. However, I still sometimes like to stay on top of recent approvals in the area. In March 2021, Janssen announced approval of ponesimod under the brand name PonVory, which is an oral medication for relapsing multiple sclerosis.

https://www.pharmaceutical-technology.com/news/fda-approves-janssen-ponvory/ (Links to an external site.)

question 3 response post

A main reason to run clinical trials globally is difference in patient population. This can refer to a lot of things such as racial demographics (bone density among other physiological features vary between races), difference in diet (American diet is higher in salt then most other diets), climate (vitamin D comes from sunlight, and there are other physiological differences associated with climates), and likelihood of taking other medications. Americans take significantly more medications than other countries, so drug-drug interactions are less likely and foreign countries than in the US. Certain infections are also more common in some countries and regions of the world than in other places.